Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...

I would like to say thank you to our shareholders, clinical collaborators, study sites and their staff, the patients who participate in our trials, and the employees of Oncolytics who have ... This ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Low testosterone or testosterone deficiency, also known as hypogonadism, is a condition in which patients develop symptoms.

My father walked out on our family when I was seven. He didn’t disappear forever. He came and went, sometimes staying for a ...